Suppression of Fungal Growth Exhibited by Pseudomonas Aeruginosa

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 1994 Feb 1

PMID 8150966

Citations 33

Authors

J R Kerr

Affiliations

Soon will be listed here.

Abstract

Three surgery patients were monitored postoperatively, with particular reference to lung infection. In each case there was a clinical impression that Pseudomonas aeruginosa suppressed the growth of Candida albicans in patients with clinically significant lung infections from whom both of these organisms were isolated from serial sputum samples. Regrowth of C. albicans after P. aeruginosa eradication occurred in two patients, despite fluconazole therapy, to which both C. albicans isolates were susceptible. In all three patients, the strain of P. aeruginosa was found to inhibit the growth of the corresponding C. albicans strain in vitro. Further in vitro susceptibility studies revealed significant inhibition by 10 strains of P. aeruginosa of 11 strains of fungi known to infect humans; these were Candida krusei, Candida keyfr, Candida guillermondii, Candida tropicalis, Candida lusitaniae, Candida parapsilosis, Candida pseudotropicalis, Candida albicans, Torulopsis glabrata, Saccharomyces cerevisiae, and Aspergillus fumigatus.

Citing Articles

Uncharted territories in the discovery of antifungal and antivirulence natural products from bacteria.

Vij R, Hube B, Brunke S Comput Struct Biotechnol J. 2021; 19:1244-1252.

PMID: 33680363 PMC: 7905183. DOI: 10.1016/j.csbj.2021.02.003.

Virulence profiles of some Pseudomonas aeruginosa clinical isolates and their association with the suppression of Candida growth in polymicrobial infections.

Abd El-Baky R, Mandour S, Ahmed E, Hashem Z, Sandle T, Mohamed D PLoS One. 2020; 15(12):e0243418.

PMID: 33290412 PMC: 7723275. DOI: 10.1371/journal.pone.0243418.

Conditional antagonism in co-cultures of Pseudomonas aeruginosa and Candida albicans: An intersection of ethanol and phosphate signaling distilled from dual-seq transcriptomics.

Doing G, Koeppen K, Occipinti P, Harty C, Hogan D PLoS Genet. 2020; 16(8):e1008783.

PMID: 32813693 PMC: 7480860. DOI: 10.1371/journal.pgen.1008783.

Bacteria Modify Hypha Formation, Microcolony Properties, and Survival within Macrophages.

Salvatori O, Kumar R, Metcalfe S, Vickerman M, Kay J, Edgerton M mSphere. 2020; 5(4).

PMID: 32759336 PMC: 7407070. DOI: 10.1128/mSphere.00689-20.

Pathogenetic Impact of Bacterial-Fungal Interactions.

Nogueira F, Sharghi S, Kuchler K, Lion T Microorganisms. 2019; 7(10).

PMID: 31623187 PMC: 6843596. DOI: 10.3390/microorganisms7100459.

References

Elander R, Mabe J, Hamill R, Gorman M . Metabolism of tryptophans by Pseudomonas aureofaciens. VI. Production of pyrrolnitrin by selected Pseudomonas species. Appl Microbiol. 1968; 16(5):753-8. PMC: 547512. DOI: 10.1128/am.16.5.753-758.1968. View

Upadhyay R, Visintin L, Jayaswal R . Environmental factors affecting the antagonism of Pseudomonas cepacia against Trichoderma viride. Can J Microbiol. 1991; 37(11):880-4. DOI: 10.1139/m91-152. View

Jayaswal R, Fernandez M, Schroeder R . Isolation and characterization of a pseudomonas strain that restricts growth of various phytopathogenic fungi. Appl Environ Microbiol. 1990; 56(4):1053-8. PMC: 184342. DOI: 10.1128/aem.56.4.1053-1058.1990. View

GORDEE R, Matthews T . Systemic antifungal activity of pyrrolnitrin. Appl Microbiol. 1969; 17(5):690-4. PMC: 377781. DOI: 10.1128/am.17.5.690-694.1969. View

Evans L, Linker A . Production and characterization of the slime polysaccharide of Pseudomonas aeruginosa. J Bacteriol. 1973; 116(2):915-24. PMC: 285463. DOI: 10.1128/jb.116.2.915-924.1973. View

Edwards Jr J . Invasive candida infections--evolution of a fungal pathogen. N Engl J Med. 1991; 324(15):1060-2. DOI: 10.1056/NEJM199104113241511. View

Arima K, Imanaka H, Kousaka M, Fukuda A, Tamura G . Studies on pyrrolnitrin, a new antibiotic. I. Isolation and properties of pyrrolnitrin. J Antibiot (Tokyo). 1965; 18(5):201-4. View

Cohen R, Roth F, Delgado E, Ahearn D, Kalser M . Fungal flora of the normal human small and large intestine. N Engl J Med. 1969; 280(12):638-41. DOI: 10.1056/NEJM196903202801204. View

GORDEE R, Matthews T . Evaluation of the in vitro and in vivo antifungal activity of pyrrolnitrin. Antimicrob Agents Chemother (Bethesda). 1967; 7:378-87. View

10.

Zhou P, Mocek U, Siesel B, Floss H . Biosynthesis of pyrrolnitrin. Incorporation of 13C, 15N double-labelled D- and L-tryptophan. J Basic Microbiol. 1992; 32(3):209-14. DOI: 10.1002/jobm.3620320312. View

11.

Govan J, Fyfe J, McMillan C . The instability of mucoid Pseudomonas aeruginosa: fluctuation test and improved stability of the mucoid form in shaken culture. J Gen Microbiol. 1979; 110(1):229-32. DOI: 10.1099/00221287-110-1-229. View

12.

GILLIES R, Govan J . Typing of Pseudomonas pyocyanea by pyocine production. J Pathol Bacteriol. 1966; 91(2):339-45. DOI: 10.1002/path.1700910207. View

13.

Tripathi R, Gottlieb D . Mechanism of action of the antifungal antibiotic pyrrolnitrin. J Bacteriol. 1969; 100(1):310-8. PMC: 315394. DOI: 10.1128/jb.100.1.310-318.1969. View

14.

Leisinger T, Margraff R . Secondary metabolites of the fluorescent pseudomonads. Microbiol Rev. 1979; 43(3):422-42. PMC: 281483. DOI: 10.1128/mr.43.3.422-442.1979. View

15.

Meunier F . Candidiasis. Eur J Clin Microbiol Infect Dis. 1989; 8(5):438-47. DOI: 10.1007/BF01964058. View